Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06434610 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06434610 · ClinicalTrials.gov record · last posted 2026-05-05

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

StatusRecruiting
PhasePhase 2
Started2024-07-11
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.

Amendment record 4 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 4 times since 2024-05-23; most recent amendment 2026-04-29. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-07-12
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT06434610
Lead Sponsor Shanghai Jiaolian Drug Research and Development Co., Ltd
Collaborators: Shanghai Pharmaceuticals Holding Co., Ltd
Conditions Platinum-resistant Recurrent Ovarian Cancer
Enrollment 90 participants
Start Date 2024-07-11
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-05